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ABSTRACT
Excitotoxicity has been implicated in the etiology of ischemic
stroke and chronic neurodegenerative disorders. Hence, the
development of novel neuroprotectant molecules that amelio-
rate excitotoxic brain damage is vigorously pursued. We used a
neuroprotection-based cellular assay to screen a synthetic
combinatorial library of N-alkylglycine trimers. Two compounds
(6-1-2 and 6-1-10) that efficiently prevented excitotoxic neuro-
degeneration in vitro and in vivo were identified. Both mole-
cules protected primary cultures of cerebellar neurons against
glutamate-induced neuronal death with an efficiency equivalent
to N-methyl-D-aspartate (NMDA) receptor antagonists. These
trialkylglycines did not block appreciably the NMDA receptor
channel, or attenuated glutamate-induced increase of Ca2, or
affect the glutamate-nitric oxide-cGMP pathway. Intraperito-
neal injection of both peptoids in mice attenuated 80% am-
monia-induced, NMDA receptor-mediated animal death. Fur-
thermore, these two molecules reduced by 50% the
neurodegeneration in striatum in a rat model of cerebral isch-
emia. Neuroprotection against ischemia was associated with
decreased activation of caspase-3, reflecting prevention of ap-
optotic neuronal death. Collectively, the results reported indi-
cate that these trialkylglycines are new neuroprotectant leads
with important in vivo activity against excitotoxicity, and that
they act on a novel, yet-unrecognized cellular target. These
lead compounds may become tolerated drugs for the treatment
of acute and chronic neurodegenerative diseases with fewer
side effects than NMDA receptor antagonists.
Glutamate is considered the main excitatory neurotrans-
mitter in mammals. However, excessive activation of gluta-
mate receptors, particularly of the NMDA receptor subtype,
leads to neuronal degeneration and death (Choi and Roth-
man, 1990). Glutamate neurotoxicity is involved in the neu-
ronal damage found in cerebral ischemia, as well as in the
pathogenesis of different neurodegenerative diseases, includ-
ing amyotrophic lateral sclerosis, and Huntington, Alzhei-
mer, and Parkinson diseases (Choi and Rothman, 1990; Kro-
emer et al., 1998). Although the underlying mechanisms for
the selective vulnerability of neurons are unknown, a widely
held view considers that excessive activation of NMDA re-
ceptor mediates a massive influx of Ca2, which induces
different effects, including alterations of the mitochondrial
potential and formation of nitric oxide and cGMP. These
alterations lead ultimately to cell death (Choi, 1987; Dawson
et al., 1991; Dawson et al., 1993; Mattson et al., 1993; Mon-
toliu et al., 1999).
Because of their central role in neurodegeneration, NMDA
receptors have been considered prime therapeutic targets for
the development of useful neuroprotective strategies
(Bra¨uner-Osborne et al., 2000). Accordingly, a significant
effort has been made to develop high-affinity and selective
NMDA antagonists that target the different drug binding
sites on this receptor. Although most of these molecules effi-
ciently reduce glutamate neurotoxicity in vitro, their in vivo
utility has been heavily questioned due to serious side effects
at clinically effective doses (Choi and Rothman, 1990; Morris
and Davis, 1995; Bra¨uner-Osborne et al., 2000). The high
receptor affinity of known NMDA receptor antagonists ap-
pears to be a major shortcoming because these compounds
This study was supported in part by grants from Fundacio´ La Marato´ de
TV3 (to V.F and A.M); Grants PM98-0065, PM99-0018, and SAF97-0001 of the
Ministerio de Educacio´n y Ciencia and of Plan Nacional de I  D of Spain (to
V.F.); grants from the Comisio´n Interministerial de Ciencia y Tecnologı´a and
the European Commission (1FD97-0662-C02-01) (to A.F.-M. and E.P.-P.) and
La Fundacio´n La Caixa (98/027-00) (to A.F.-M.); and from Comisio´n Intermin-
isterial de Ciencia y Tecnologı´a (SAF98-0059) (to A.M.). J.J.-C. has a Contrato
de Reincorporacio´n of the Ministerio de Educacio´n, Cultura y Deporte of Spain.
ABBREVIATIONS: NMDA, N-methyl-D-aspartate; MK-801, (SR,10S)-()-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine hydro-
gen maleate.
0022-3565/02/3011-29–36$7.00
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Vol. 301, No. 1
Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics 4530/972764
JPET 301:29–36, 2002 Printed in U.S.A.
29
bind to both pathologically activated and physiologically
working NMDA receptor populations (Choi and Rothman,
1990; Kroemer et al., 1998). Because NMDA receptors are
implicated in learning and memory, inhibition of glutama-
tergic neurotransmission may underlie the cognitive deficits
provoked by high-affinity NMDA receptor antagonists (Mor-
ris and Davis, 1995). In addition, it has been reported that
chronic administration of these antagonists enhances neuro-
nal death (Ikonomidou et al., 2000; Olney et al., 2000). Ther-
apeutic alternatives that may significantly overcome these
deficiencies involve the use of uncompetitive NMDA antago-
nists (Lipton and Rosenburg, 1994; Ferrer-Montiel et al.,
1998), NMDA receptor subtype-specific blockers (Chenard
and Menniti, 1999; Bra¨uner-Osborne et al., 2000), or NMDA
receptor-directed oral vaccines (During et al., 2000).
Alternatively, molecules that prevent neuronal death by
acting on other cellular targets involved in neurodegenera-
tion onset may be therapeutically useful to ameliorate the
harmful consequences of excitotoxicity. These compounds
may be devoid of the adverse in vivo effects of well estab-
lished NMDA antagonists. To address this issue, we have
used a neuroprotection-based cellular assay to identify neu-
roprotectant molecules from a combinatorial library of oligo
N-substituted glycines (Fig. 1). At variance with biological
assays that focus on receptor activity, we have evaluated the
efficiency of combinatorial mixtures preventing glutamate-
induced neuronal death directly on primary cultures of cer-
ebellar neurons. Library deconvolution identified a family of
trialkylglycines that efficiently reduced excitotoxic cell death
in cultured neurons (Fig. 2). Noteworthy, intraperitoneal ad-
ministration of compounds N-[2-(N-pyrrolidinyl)ethyl]gly-
cyl]-[N-[cyclopropyl]glycyl]-N-(sec-butyl)glycinamide (re-
ferred to as 6-1-2) and [N-[2-(N-pyrrolidinyl)ethyl]glycyl]-[N-
[cyclopropyl]glycyl]-N-(2-phenethyl)glycinamide (denoted as
6-1-10) significantly protected mice against ammonia-
induced, NMDA receptor-mediated animal death. In addi-
tion, these two peptoids remarkably prevented the neuronal
apoptosis induced by cerebral ischemia in rats. Both com-
pounds are novel neuroprotectants that act on an as yet-
unrecognized cellular target. Because these neuroprotectant
peptoids do not block the NMDA receptor, the psychotropic




Basal Eagle’s medium, fetal bovine serum, and gentamycin were
from Invitrogen (Rockville, MD). DNase I (E.C. 3.1.21.1) and dispase
II were from Roche Applied Science (Mannheim, Germany). Gluta-
mate and NMDA were from Sigma Chemical (St. Louis, MO). Fluo-
rescein diacetate, propidium iodide, and fluo-3/AM were from Molec-
ular Probes (Leuven, Belgium). Culture plates were from Costar
(Cambridge, MA). The kit for cGMP determination was from Amer-
sham plc (Little Chalfont, Buckinghamshire, UK).
Synthesis of Library of N-Alkylglycines
A library of 10,648 compounds in 66 controlled mixtures was
synthesized by using the positional scanning format in solid phase
(Pinilla et al., 1992; Figliozzi et al., 1996). In our case, a collection of
22 commercially available primary amines was used for introducing
the desired chemical diversity in the library. The details of this
synthesis will be described elsewhere (M. Humet, T. Carbonell, F.
Sa´nchez-Baeza, P. Mora, E. Canto´n, M. Bobernado, E. Percz-Paya,
and A. Messeguer, manuscript in preparation). Briefly, starting from
Rink amide resin (Rapp Polymere, 0.7 meq) the eight-step synthetic
pathway involved the initial release of the Fmoc protecting group.
Then the successive steps of acylation with chloroacetyl chloride
followed by the corresponding amination of the chloromethyl inter-
mediate using the particular primary amine, or the equimolecular
mixture of the 22 amines was conducted as appropriate. All these
reactions were carried out in duplicate. Finally, the products were
released from the resin by using a trifluoroacetic acid/dichlorometh-
ane/water mixture, solvents were evaporated, and the residues were
lyophilized and dissolved in 10% dimethyl sulfoxide at the concen-
tration of 10 mg/ml for screening of neuroprotection.
Synthesis of Individual Neuroprotective Trialkylglycines
The results from the screening of the 66 mixtures of the peptoid
library led to a deconvolution process from which the synthesis of 12
individual molecules was derived. These trialkylglycines were pre-
pared on solid phase following the same synthetic scheme but using
the N-hydroxysuccinimide ester of chlorocaetic acid as acylating
agent and the appropriate amines for the amination steps. The
screening of these library members in the in vitro test led to the final
selection of two trimers (612 and 6110; Fig. 2) as the most active
candidates for performing the in vivo assays. Crude compounds 612
and 6110 obtained from the release of the resin were purified by
preparative reversed phase high-performance liquid chromatogra-
phy using a 250-  20-mm column packed with 5-m Kromasil C-8.
Methanol and water, both containing 0.1% trifluoroacetic acid, were
used as a mobile phases at 6 ml/min, under the following elution
conditions: 20:80 methanol/water during 2 min and then gradient up
to 100% methanol in 30 min. Eluates were collected, methanol was
removed under vacuum, and the residues were lyophilized to render
the desired compounds (95% purity by high-performance liquid
chromatography).
612. 1H-NMR (500 MHz, 10°C in D2O, mixture of conformers), 
from N-terminal to C-terminal: 2.04–1.89 (m, 4H, CH2CH2N pyrro-
lidine), 3.01–3.61 (m, 4H, CH2N pyrrolidine), 3.52 (t, 2H,
CH2CH2NH), 3.45 (t, 2H, CH2NH), 4.31(s, 2H, CH2CO), 2.73 (m, 1H,
CHN), 0.69–0.80 (m, 4H, (CH2)2CHN), 4.35 (s, 2H, CH2CO), 3.73 (m,
1H, CH3CHCH2CH3), 1.43 (m, 2H, CH3CHCH2CH3), 0.76 (m, 3H,
CH3CHCH2CH3), 1.07 (m, 3H, CH3CHCH2CH3), 3.72–3.89 (m, 2H,
CH2CO).
13C-NMR (500 MHz, 10°C in D20),  from N-terminal to
C-terminal: 24.8 (CH2CH2N pyrrolidine), 57.2 (CH2N pyrrolidine),
52.2 (CH2CH2NH), 45.2 (CH2NH), 48.0 (CH2CO), 171.0 (CO), 10.1
((CH2)2CHN), 32.5 (CHN), 51.9 (CH2CO), 172.1 (CO), 56.8
(CH3CHCH2CH3), 29.4 (CH3CHCH2CH3), 12.5 (CH3CHCH2CH3),
19.8 (CH3CHCH2CH3), 46.0 (CH2CO), 176.0 (CO). HRMS: MS Cal-
culated for C19H36N5O3 382.281815. Found: 382.282518.
6110. 1H-NMR (500 MHz, 10°C in D2O, mixture of conformers), 
from N-terminal to C-terminal: 2.01–2.17 (m, 4H, CH2CH2N pyrro-
lidine), 3.11–3.72 (m, 4H, CH2N pyrrolidine), 3.59 (t, 2H,
CH2CH2NH), 3.50 (t, 2H, CH2NH), 4.31 and 4.38 (s, 2H, CH2CO),
2.67 and 2.80 (m, 1H, CHN), 0.58–0.92 (m, 4H, (CH2)2CHN), 3.88
and 4.22 (s, 2H, CH2CO), 7.30–7.42 (m, 5H, H Arom), 2.95–2.84 (m,
2H, CH2CH2NH), 3.59–3.67 (m, 2H, CH2N), 4.05 (s, 2H, CH2CO).
13C-NMR (500 MHz, 10°C in D20),  from N-terminal to C-terminal:
21.7 (CH2CH2N), 54.0 (CH2N), 48.8 (CH2CH2NH), 41.9 (CH2NH),
48.0 (CH2CO), 167.8 (CO), 7.0 ((CH2)2CHN), 29.4 (CHN), 48.3 and
48.4 (CH2CO), 169.1 and 169.0 (CO), 49.4 (CH2CH2N), 32.6 (CH2N),
137.3 (C arom), 128.3 (CH orto arom), 128.2 (CH meta arom), 126.3Fig. 1. Chemical structure of the library of N-alkylglycine trimers.
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(CH para arom), 47.9 (CH2CO), 172.1 (CO). HRMS: MS calculated
for C23H36N5O3 430.281815. Found: 430.283409.
Primary Cultures of Neurons
Primary cultures of cerebellar neurons were prepared using cere-
bella from 7- to 8-day-old Wistar rats as described (Min˜ana et al.,
1998). Neurons were grown at 37°C in 5% CO2 atmosphere. To
prevent proliferation of non-neuronal cells, 10 M cytosine arabino-
side was added 24 h after plating. Glucose, 5.6 mM final concentra-
tion, was added to the culture medium twice a week.
Assay of Protection against Glutamate Neurotoxicity
Glutamate toxicity in cerebellar neurons was assayed after 11 to
15 days of culture. Briefly, culture medium was removed and kept at
37°C (conditioned medium). Cells were washed and incubated at
37°C for 20 min with Mg2-free Locke’s solution (154 mM NaCl, 5.6
mM KCl, 3.6 mM NaHCO3, 2.3 mM CaCl2, 5.6 mM glucose, 5 mM
HEPES, pH 7.4), containing 10 M glycine. Thereafter, this solution
was removed and cells were incubated with 1 mM glutamate in
Mg2-free Locke’s solution without glycine at 37°C for 4 h. Preincu-
bation with glycine was convenient to obtain more reproducible
results when comparing different culture preparations. Individual
peptoids were added 20 min before glutamate addition. Cells were
washed with Mg2-free Locke’s solution and the conditioned medium
previously removed was added again. Cell viability was measured
24 h later by staining with fluorescein diacetate and propidium
iodide as previously described (Felipo et al., 1993). The percentage of
surviving neurons was calculated by assessing the ratio of fluores-
cein diacetate/propidium iodide (green/red) staining directly under
the microscope. At least 1200 cells were counted for each data point.
Determination of cGMP in Cultured Neurons
Neurons were used 11 to 15 days after seeding. Monolayers were
washed three times with prewarmed Mg2-free Locke’s solution. The
assay of NMDA-induced formation of cGMP was carried out in the
same medium. Treatments with 1 mM NMDA were at 37°C for 5
min. cGMP was determined using the BIOTRAK cGMP enzyme
immunoassay kit from Amersham plc as described (Montoliu et al.,
1999). For each experiment, samples were measured in duplicate.
Determination of Free Intracellular Calcium
Changes in intracellular free Ca2 were monitored in single neu-
rons using an ACAS 570 confocal laser cytometer (Meridians Instru-
ments, Okemos, MI). Primary cultures of cerebellar neurons were
plated on 35-mm tissue culture dishes and loaded with 20 M Fluo-
3/AM in the culture medium at 37°C for 1 h. Thereafter, the cells
were washed twice with prewarmed Mg2-free Locke’s solution, and
1 ml of the same solution was added. To study the effects of the
peptoids on free intracellular Ca2 levels, each peptoid was added to
the medium, the fluorescence was recorded for the time desired, and
250 M glutamate or NMDA was then added. Ca2 levels were
monitored continuously. Free intracellular calcium was quantified
using the confocal laser cytometer as previously described (Marcaida
et al., 1995a). Each experiment was repeated at least four times with
three different neuronal cultures.
Prevention of Ammonia-Induced, NMDA Receptor-
Mediated Death of Mice
Acute ammonia intoxication leads to excessive activation of
NMDA receptors in brain (Hermenegildo et al., 2000), which is
responsible for ammonia-induced death of animals (Marcaida et al.,
1992; Hermenegildo et al., 1996). Male Swiss mice (25–35 g) were
injected i.p. with 14 mmol/kg (3 l/g) of ammonium acetate. To assess
the protective effect of peptoids, these were injected i.p. 10 min
before ammonium injection. The number of mice surviving 24 h after
injection was counted.
Transient Bilateral Hemispheric Ischemia: Surgery and
Treatments with Peptoids
For the transient forebrain ischemia experiments, we used the
four-vessel occlusion model of Pulsinelli and Brierley (1979) with the
modifications of Schmidt-Kastner et al. (1989). Briefly, rats were
anesthetized with 120 g/g ketamine and 15 g/g xylazine and
placed in a rat holder. Vertebral arteries were coagulated perma-
nently at the level of the lateral vertebral foramen with the aid of an
electrocauter device. After 24 h, we clamped temporarily (15 min) the
two common carotids under halothane anesthesia. Rats received i.p.
injections of the peptoids (50 g/g; 2.5 l/g) three times: 15 min
before occlusion of the carotids, immediately after removal of the
carotid clamp, and at 24 h of reperfusion. After a 7-day survival
period, rats were deeply anesthetized with sodium pentobarbital and
perfused transcardially with 0.9% saline followed by 4% paraformal-
dehyde in phosphate buffer (0.1 M NaKPO4). The brains were re-
moved and stored in 30% sucrose in phosphate buffer until further
processing.
Detection of Neurodegeneration by Silver Impregnation
For the detection of neuronal somata, axons, and terminals un-
dergoing degeneration, free-floating 50-m-thick sagittal sections
were stained with a silver impregnation protocol (FD NeuroSilver kit
I; FD Neurotechnologies, Baltimore, MD) (Gallyas et al., 1992; Bel-
tramino et al., 1993). Degenerating neurons and axons appeared
stained black against a background of relatively spared neural pro-
cesses stained yellow/brown (Fig. 7).
Detection of Neurons Showing Activated Caspase-3
Free-floating 25-m-thick sagittal sections of the same brains
were treated with standard single-antigen immunohistochemical
methods. Sections were exposed to hydrogen peroxide, blocked, and
incubated overnight with antiserum raised against the large frag-
ment of activated caspase-3, resulting from cleavage after aspartic
acid at position 175 (1:100; Cell Signaling Technology Inc., Beverly,
MA). Sections were then incubated with biotinylated secondary an-
tiserum and with the avidin-biotin complex (ABC kit; Vector Labo-
ratories, Burlingame, CA). The horseradish peroxidase reaction
products were visualized with diaminobenzidine and intensified with
nickel sulfate, appearing as discrete black precipitates (Fig. 8).
Fig. 2. Structures of 6-1-2 and 6-1-10, two representative neuroprotective agents derived from the library of N-alkylglycine trimers.
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Quantification
For the sections stained with the silver impregnation method, we
estimated the area in the dorsal striatum showing dense silver
precipitates. Between three and five sections were averaged per
animal. For the sections processed for immunohistochemistry,
caspase-3-positive cells were counted within a rectangular area of ca.
1.5 mm2 at the level of the dorsal striatum, caudally (Fig. 7). At least
four adjacent sections were averaged per animal. Estimations of
ischemic injury as measured by the silver method and counts for
active caspase-3 immunoreactivity were carried out blind to the
experimental treatments.
Statistics
Results of Figs. 3, 4, and 6 were analyzed by one-way analysis of
variance followed by post hoc Dunnett’s test or Student’s t test using
the PRISM program (version 2.0; GraphPad Software, San Diego,
CA) and the results of Fig. 8 were analyzed by Tukey-Kramer test.
All animal experiments were carried out in accordance to the
European Union Guidelines for Care and Use of Laboratory Animals.
All efforts were made to minimize animal suffering.
Results
Identification of Novel Neuroprotectant Molecules
from a Library of Trialkylglycines. A positional scan-
ning, mixture-based combinatorial library composed of trim-
ers of N-alkylglycines was screened to identify molecules that
prevent glutamate-induced neuronal death in primary cul-
tures of cerebellar neurons. The design of this library con-
tained two distinctive features. First, the use of the posi-
tional scanning format strategy for its construction. Second,
the selection of the diversity included the use primary
amines bearing an additional tertiary amino moiety. The
introduction of these amines conducted to trimers containing
additional protonable fragments, which could complement
the activity pattern and bioavailability of the library mem-
bers. The general structure of the trimers is shown in Fig. 1.
The library was organized in 66 mixtures, each containing
484 molecules, giving rise to a chemical diversity of 10,648
individual trialkylglycines. Screening of the 66 mixtures
identified the preferred diversity at the three separate posi-
tions (R1, R2, and R3) of the oligomer (Fig. 1). At the R1
position the selected amines were cyclopropyl (denoted as
amine 1) and 2-N-pyrrolidinyl (denoted as amine 6); at the R2
position were cyclopropyl and 2-(N-morpholino)ethyl (denot-
ed as amine 18); and at the R3 position were sec-butyl (de-
noted as amine 2), 2-phenylethyl (amine 10), and 2,4-(amin-
osulphonylphenyl)ethyl (amine 17).
When used in concert, these results suggest the chemical
identity of potential neuroprotectant molecules. Hence, we
synthesized a family of the individual peptoids containing
the different combinations of the above-mentioned amines
and assayed their activity preventing glutamate-induced
neuronal death. The structures of two of these compounds
are shown in Fig. 2. As illustrated in Fig. 3, several of these
peptoids exhibited remarkable neuroprotective activity at 50
g/ml (100 M).
Because most of the active peptoid exhibit a similar neu-
roprotective efficacy, further characterization was focused on
two of these peptoids, 6-1-2 and 6-1-10. These compounds
were purified and rigorously characterized by analytical and
spectroscopic means.
Dose-response studies showed that concentrations as low
as 1 g/ml (2 M) prevented 20% neuronal culture neuro-
degeneration. The effect was maximal at 50 g/ml (100 M)
with a 70% neuroprotection (Fig. 4A). For compound 6-1-2
the IC50 (concentration of peptoid that prevented half of
maximal neurodegeneration) was 8 M and for 6-1-10 was
15 M. Therefore, these newly identified trialkylglycine-
based molecules are potent neuroprotectants.
Trialkylglycine-Based Neuroprotectants Do Not In-
hibit Activation of NMDA Receptor. To gain insights on
the mechanism underlying the neuroprotective activity of
these trialkylglycines, we investigated whether they act as
antagonists of NMDA receptors. We determined whether
these peptoids reduced the raise in intracellular Ca2 in-
duced by activation of NMDA receptor by L-glutamate or
Fig. 3. Protective effect of peptoids against glutamate neurotoxicity in
primary cultures of cerebellar neurons. Primary cultures of cerebellar
neurons were used 10 to 14 days after seeding. Neurons were treated with
1 mM glutamate after preincubation for 15 min with 50 g/ml of the
indicated peptoids. Neuronal viability was determined as indicated under
Experimental Procedures. At least 1200 cells/point were counted in each
assay. Values are the mean standard deviations of six assays using five
different cultures. Values that are significantly different from controls
(p  0.001) are indicated by asterisks.
Fig. 4. Concentration dependence of the protective effect of peptoids on
glutamate neurotoxicity in primary cultures of cerebellar neurons. Pri-
mary cultures of cerebellar neurons were used 10 to 14 days after seeding.
Neurons were treated with 1 mM glutamate after preincubation for 15
min with the indicated concentrations of the different peptoids and cell
viability was determined as indicated under Experimental Procedures. At
least 1200 cells/point were counted in each assay. Values are the mean 
standard deviations of five to six assays using four to six different cul-
tures. Values that are significantly different from controls (p 0.001) are
indicated by asterisks.
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NMDA. As depicted in Fig. 5, the NMDA receptor-mediated
increase in intracellular Ca2 was not significantly altered
by addition of compounds 6-1-2 and 6-1-10 to the extracellu-
lar medium before and during treatment with the agonist.
The lack of inhibitory effect was independent of the agonist
used because similar results were obtained with glutamate
or NMDA. In contrast, addition of MK-801 drastically pre-
vented Ca2 influx (Fig. 5). Consistent with this notion, both
peptoids did not significantly block the glutamate-evoked
ionic currents from recombinant rat brain NMDA receptors
heterologously expressed in Xenopus oocytes (25  5% at 50
M; data not shown). These findings imply that these pep-
toids do not inhibit NMDA receptor activity.
Trialkylglycines Do Not Alter Glutamate-Induced
cGMP Production in Neurons. Activation of the NMDA
receptor leads to production of cGMP through the glutamate-
nitric oxide-cGMP pathway. It has been shown that inhibi-
tion of this signaling pathway prevents glutamate neurotox-
icity (Dawson et al., 1991; Lafon-Cazal et al., 1993; Marcaida
et al., 1995b) and that inhibition of glutamate-induced for-
mation of cGMP by using inhibitors of soluble guanylate
cyclase prevents glutamate-induced neuronal death in cere-
bellar neurons in culture (Hermenegildo et al., 1998; Monto-
liu et al., 1999). To assess whether the protective peptoids
interfere with any step of this pathway, we next investigated
whether identified trialkylglycines decreased the production
of cGMP in cultured cerebellar neurons treated with NMDA.
As shown in Fig. 6, none of the peptoids affected the NMDA-
induced production of cGMP. Therefore, the neuroprotective
activity exerted by these molecules is not due to inhibition of
any of the steps of this signaling pathway.
Trialkylglycines Prevent Ammonia-Induced, NMDA
Receptor-Mediated Death of Mice. To assess the protec-
tive activity of identified peptoids in vivo, we next investi-
gated whether compounds 6-1-2 and 6-1-10 were able to
prevent death in an animal model of glutamate-mediated
neurotoxicity. Intraperitoneal administration of high doses of
ammonium acetate leads to animal death. Ammonia lethality
is mediated by excessive activation of NMDA receptors (Her-
menegildo et al., 1996, 2000). We used this model to evaluate
Fig. 5. Peptoids do not prevent glutamate- or NMDA-induced increase in
free intracellular Ca2 in neurons. Primary cultures of cerebellar neurons
were prepared using 35-mm-diameter tissue culture dishes and were
used 10 to 14 days after seeding. Free intracellular calcium content was
determined with fluo-3/AM using a confocal microscope. For controls the
basal calcium level was recorded for 200 s, then the agonist (250 pM
NMDA or glutamate) was added (indicated by vertical line), and the
fluorescence was recorded for the indicated time. For assaying the effect
of peptoids or MK-801 the basal calcium level was recorded for 200 s.
Peptoid (50 pg/ml) or MK-801 (1 M) was then added (first vertical line),
and the fluorescence was recorded for 600 s, followed by addition of the
agonist (second vertical line).
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the in vivo protective activity of trialkylglycines 6-1-2 and
6-1-10 (Table 1). Notably, intraperitoneal injection of 50 g/g
peptoid 6-1-2, 10 min before injection of ammonia, afforded a
complete protection against ammonia-induced death of mice
(24 of 24 mice survived to ammonia intoxication), whereas
only 16% of mice injected with saline survived. Similarly,
treatment with 50 g/g peptoid 6-1-10 protected 82% of mice.
These results are comparable to those reported for NMDA
receptor antagonists (Hermenegildo et al., 1996, 2000). Thus,
identified peptoids exhibit in vivo neuroprotectant activity.
Trialkylglycines Prevent Ischemic Neurodegenera-
tion in Rats. To further characterize the in vivo activity of
these peptoids, we evaluated their beneficial effect in pre-
venting the neuronal damage provoked by cerebral ischemia.
For these experiments, peptoids (50 g/g) were administered
to rats 15 min before provoking the ischemic insult, as well as
1 and 24 h after the ischemia onset. Animals were sacrificed
7 days later and the extent of brain damage was evaluated.
As shown in Fig. 7, the ischemic insult provoked by transient
occlusion of the carotids produced extensive degeneration in
the dorsal and caudal aspects of the caudoputamen, mainly
Fig. 6. Effects of peptoids on NMDA-induced formation of cGMP in neurons.
Neuronal cultures were used 10 to 14 days after seeding. Cells were washed
in Mg2-free Locke’s solution and preincubated with the same solution for 20
min at 37°C. Then 50 g/ml of the indicated peptoids were added and
incubated for 15 min before addition of NMDA (1 mM final concentration).
Basal and NMDA-induced formation of cGMP were measured as indicated
under Experimental Procedures. For each experiment, the basal level of
formation cGMP in control neurons was considered as 100%. Values are the
mean  standard deviations of duplicate samples from five experiments
using four different cultures. All values with NMDA alone NMDA peptoid
are significantly different (p  0.001) from basal.
Fig. 7. Peptoids 6-1-2 and 6-1-10 prevent
neurodegeneration induced in striatum
by ischemia. Rats were subjected to tran-
sient ischemia, with or without treatment
with peptoids 6-1-2 or 6-1-10 as described
under Experimental Procedures. Degener-
ation neurons were visualized by the sil-
ver impregnation method and given the
dark staining shown in c. a, diagram rep-
resenting the rectangular area of the cau-
doputamen considered for quantification
purposes. b, control rat. c, rat subjected to
ischemia without treatments. d, rat
treated with peptoid 6-1-10 and subjected
to ischemia. e, rat treated with peptoid
6-1-2 and subjected to ischemia. Similar
results were obtained in two different rats
per group. CX, cerebral cortex; STR, stri-
atum; HIP, hippocampus.
TABLE 1
Peptoids 6-1-2 and 6-1-10 prevent ammonia-induced, NMDA receptor-
mediated death of mice
Male Swiss mice weighing 25 to 35 g were used. Peptoids were injected intraperito-
neally 10 min before ammonium injection. Ammonium acetate (14 mmol/kg) was also
injected intraperitoneally. The concentrations of the solutions were adjusted to reach
the desired dose by injecting 3 l per gram of body weight. The number of surviving
mice was counted 24 h after ammonium injection. All animals surviving at this time
remained alive for several weeks until they were sacrificed.
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in the immediate environs of the lateral ventricle. In animals
exposed to transient ischemia, areas of dark silver stain
extended rostrally in the lateral, sensorimotor area of the
caudoputamen. The administration of the peptoids notably
prevented the neuronal damage provoked by ischemia, as
revealed by the significant decrease in silver accumulation in
the dorsal caudoputamen. Peptoid 6-1-10 reduced the esti-
mated area of insult by 65% and peptoid 6-1-2 by 82% (Fig. 7).
It has been reported that many neurons undergo apoptosis
after ischemia (Choi and Rothman, 1990). We questioned
whether selected peptoids may also attenuate ischemia-in-
duced neuronal apoptosis. For this task, we monitored the
content of activated caspase-3 in the striatum of control and
peptoid-treated rats that suffered an ischemic attack. As
shown in Fig. 8, ischemia induced a significant activation of
caspase-3 in control animals, reflecting induction of apopto-
sis in a large number of neurons. In marked contrast, ani-
mals treated with 50 g/g i.p. peptoids exhibited a significant
reduction in caspase-3 activation in the same brain region.
Noticeably, peptoid 6-1-2 decreased by 74% the number of
apoptotic neurons, and peptoid 6-1-10 by 50% (Fig. 8E).
Therefore, these trialkylglycines reduce the infarct volume
after transient ischemia in rats.
Discussion
Neurodegeneration is a multifaceted process involving,
among others, the unbalance of the glutamatergic system.
Prolonged exposure of neurons to moderate-to-high concen-
trations of L-glutamate irreversibly culminates in neuronal
damage. It is generally accepted that the influx of Ca2 as a
result of excessive activation of the NMDA receptor underlies
the toxic actions of glutamate in many systems. (S)--Amino-
2,3-dyhydro-5-methyl-3-oxo-4-isoxazolepropanoic acid recep-
tors also mediate glutamate neurotoxicity under certain con-
ditions (Choi and Rothman, 1990; Lee and Choi, 1999). The
pivotal role assigned to NMDA receptors in neurodegenera-
tion has signaled this channel protein as prime target for
neuroprotectant drug development. However, much of the
initial enthusiasm has declined because of poor performance
of NMDA receptor antagonists in clinical trials (Choi and
Rothman, 1990; Garthwaite, 1995). Apparently, the clinical
unsuitability of these compounds may arise, at least par-
tially, from their psychotomimetic effects, especially for slow-
developing neurodegeneration (Choi and Rothman, 1990;
Chase and Oh, 2000). Moreover, it has been reported that
NMDA antagonists may enhance neuronal death in vivo
(Ikonomidou et al., 1999; Olney et al., 2000). Accordingly,
new therapeutic approaches that attenuate excitotoxicity
should be evaluated and developed. To pursue this goal, we
used a neuroprotection-based cellular assay suitable to
screen combinatorial libraries composed either of mixtures or
of individual compounds. At variance with target-directed
screenings, our assay directly evaluates the efficiency of mol-
ecules attenuating glutamate-induced neuronal death. A sa-
Fig. 8. Peptoids 6-1-2 and 6-1-10 prevent ac-
tivation of caspase-3 induced in striatum by
ischemia. Rats were subjected to transient
ischemia, with or without treatment with
peptoids 6-1-2 or 6-1-10 as described under
Experimental Procedures. Distribution of ac-
tivated caspase-3 in parasagittal sections of
the caudoputamen after ischemia treatments
was detected using a specific antibody as de-
scribed under Experimental Procedures. a,
control rat. b, rat subjected to ischemia with-
out treatments. c, rat treated with peptoid
6-1-10 and subjected to ischemia. d, rat
treated with peptoid 6-1-2 and subjected to
ischemia. Similar results were obtained in
two different rats per group. e, inhibition of
ischemia-induced expression of caspase-3 by
peptoid treatments. Analysis of variance
showed a significant effect of treatment
[F(3,9)  12.976, p  0.001]. , p  0.05; ,
p  0.01 (Tukey-Kramer test).
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lient application of this cellular assay is the identification of
a novel class of trialkylglycine-based neuroprotectant mole-
cules that significantly prevents excitotoxic neuronal death
in in vitro and in vivo models of neurodegeneration. Oli-
gomers of N-substituted glycines provide a class of small,
non-natural molecules that are proteolytically stable and
have potent biological activities (Ostergaard and Holm,
1997). A major advantage of using short oligomers is that
they usually display acceptable tissue penetration properties
and better pharmacological conformities (Lipinski et al.,
1997; Newton, 1999).
Two peptoids, 6-1-2 and 6-1-10, protected primary neuro-
nal cultures against the deleterious glutamate neurotoxicity
with efficiencies that rival those characteristics of NMDA
receptor antagonists. Of significance, both peptoids at 50
g/g displayed remarkable neuroprotective activity in two in
vivo models of acute excitotoxicity, namely, acute ammonia
intoxication and transient ischemia. Thus, these novel pep-
toids may be considered leads for drug development.
The neuroprotective activity exerted by these peptoids does
not appear to be mediated by blockade of the NMDA receptor
or by attenuation of glutamate/NMDA-induced Ca2 influx.
These observations suggest that newly identified molecules
may interfere with signaling steps downstream in the gluta-
mate-nitric oxide-cGMP cascade. However, our data demon-
strate that trialkylglycines did not alter glutamate-induced
neuronal cGMP synthesis, thus ruling out inhibition of nitric-
oxide synthase or guanylate cyclase. Furthermore, we have
also observed that neither of these compounds inhibit the
enzymatic activity of caspase-3 (data not shown). The ques-
tion that arises is, What is the molecular mechanism under-
lying the neuroprotective activity of selected peptoids? Our
studies show that these peptoids prevent neuronal death
without attenuating glutamate-mediated neuronal Ca2
overload. Additional studies are required to unequivocally
uncover the molecular entity targeted by these compounds.
The development of this new class of neuroprotectant mol-
ecules may provide novel therapies for the treatment of dis-
orders involving excessive activation of glutamate receptors
such as neuronal damage in ischemia and several neurode-
generative and psychiatric disorders. Because these mole-
cules do not block the NMDA receptor they may not exhibit
the unwanted side effects that appear after chronic admin-
istration of NMDA receptor antagonists. Furthermore, be-
cause these peptoids appear to block ischemia-induced apo-
ptosis they might be also useful in a therapeutic approach
directed to dual inhibition of excitotoxic necrosis and apopto-
sis (Lee and Choi, 1999).
References
Beltramino CA, de Olmos JS, Gallyas F, Heimer L, and Zaborszky L (1993) Silver
staining as a tool for neurotoxic assessment. NIDA Res Monogr 136:101–125.
Bra¨uner-Osborne H, Egebjerg J, Nielsen E, Madsen U, and Krogsgaard-Larsen P
(2000) Ligands for glutamate receptors: design and therapeutic prospects. J Med
Chem 43:2609–2645.
Chase TN and Oh JD (2000) Striatal mechanisms and pathogenesis of parkinsonian
signs and motor complications. Ann Neurol 47 (Suppl 1):122–129.
Chenard BL and Menniti FS (1999) Antagonists selective for NMDA receptors
containing the NR2B subunit. Curr Pharmacol Des 5:381–404.
Choi DW (1987) Ionic dependence of glutamate neurotoxicity. J Neurosci 7:369–379.
Choi DW and Rothman SM (1990) The role of glutamate neurotoxicity in hypoxic-
ischemic neuronal death. Annu Rev Neurosci 13:171–182.
Dawson VL, Dawson T, Bartley DA, Uhl GR, and Snyder SH (1993) Mechanisms of
nitric oxide-mediated neurotoxicity in primary brain cultures. J Neurosci 13:2651–
2661.
Dawson VL, Dawson T, London ED, Bredt DS, and Snyder SH (1991) Nitric oxide
mediates glutamate neurotoxicity in primary cortical cultures. Proc Natl Acad Sci
USA 88:6368–6371.
During MJ, Symes CW, Lawlor PA, Lin J, Dunning J, Fitzsimons HL, Poulsen D,
Leone P, Xu R, Dicker BL, Lipski J, and Young D (2000) An oral vaccine against
NMDAR1 with efficacy in experimental stroke and epilepsy. Science (Wash DC)
287:1453–1460.
Felipo V, Min˜ana MD, and Grisolı´a S (1993) Inhibitors of protein kinase C prevent
the toxicity of glutamate in primary neuronal cultures. Brain Res 604:192–196.
Ferrer-Montiel AV, Merino JM, Blondelle SE, Pe´rez-Paya´ E, Houghten RA, and
Montal M (1998) Selected peptides targeted to the NMDA receptor channel protect
neurons from excitotoxic death. Nat Biotech 16:286–291.
Figliozzi GM, Goldsmith R, Ng SC, Banville SC, and Zuckermann RN (1996) Syn-
thesis of N-substituted glycine peptoid libraries. Methods Enzymol 267:437–447.
Gallyas F, Zoltay G, and Dames W (1992) Formation of “dark” (argyrophilic) neurons
of various origin proceeds with a common mechanism of biophysical nature (a
novel hypothesis). Acta Neuropathol 83:504–509.
Garthwaite J (1995) NMDA receptors, neuronal development, and neurodegenera-
tion, in The NMDA Receptor (Collingridge GL ed) pp 428–457, Oxford University
Press, Oxford.
Hermenegildo C, Marcaida G, Montoliu C, Grisolı´a S, Min˜ana MD, and Felipo V
(1996) NMDA receptor antagonists prevent acute ammonia toxicity in mice. Neu-
rochem Res 21:1237–1244.
Hermenegildo C, Monfort P, and Felipo V (2000) Activation of N-methyl-D-aspartate
receptors in rat brain in vivo following acute ammonia intoxication: characteriza-
tion by in vivo brain microdialysis. Hepatology 31:709–715.
Hermenegildo C, Montoliu C, Llansola M, Mun˜oz MD, Gaztelu JM, Min˜ana MD, and
Felipo V (1998) Chronic hyperammonemia impairs glutamate-nitric oxide-cyclic
GMP pathway in cerebellar neurons in culture and in the rat in vivo. Eur J Neu-
rosci 10:3201–3209.
Ikonomidou C, Bosch F, Miksa M, Bittigau P, Vockler J, Dikranian K, Tenkova TI,
Stefovska V, Turski L, and Olney JW (1999) Blockade of NMDA receptors and
apoptotic neurodegeneration in the developing brain. Science (Wash DC) 283:70–
74.
Ikonomidou C, Stefovska V, and Turski L (2000) Neuronal death enhanced by
N-methyl-D-aspartate antagonists. Proc Natl Acad Sci USA 97:12885–12890.
Kroemer G, Dallaporta B, and Reche-Rigon M (1998) The mitochondrial death/life
regulator in apoptosis and necrosis. Annu Rev Physiol 60:619–642.
Lafon-Cazal M, Culcasi M, Gaven F, Pietri S, and Bockaert J (1993) Nitric oxide,
superoxide and peroxynitrite: putative mediators of NMDA-induced cell death in
cerebellar granule cells. Neuropharmacology 32:1259–1266
Lipinski CA, Lombardo F, Dominy BW, and Fenney PJ (1997) Experimental and
computational approaches to estimate solubility and permeability in drug discov-
ery and development settings. Adv Drug Deliv Res 23:3–25.
Lipton SA and Rosenburg PA (1994) Excitatory amino acids as a final common
pathway for neurologic disorders. New Engl J Med 330:613–622.
Marcaida G, Felipo V, Hermenegildo C, Min˜ana MD, and Grisolı´a S (1992) Acute
ammonia toxicity is mediated by NMDA type of glutamate receptors. FEBS Lett
296:67–68.
Marcaida G, Min˜ana MD, Burgal M, Grisolı´a S, and Felipo V (1995a) Ammonia
prevents activation of NMDA receptors by glutamate in rat cerebellar neuronal
cultures. Eur J Neurosci 7:2389–2395.
Marcaida G, Min˜ana MD, Grisolı´a S, and Felipo V (1995b) Lack of correlation
between glutamate-induced depletion of ATP and neuronal death in primary
cultures of cerebellum. Brain Res 695:146–150.
Mattson MP, Zhang Y, and Bose S (1993) Growth factors prevent mitochondrial
dysfunction, loss of calcium homeostasis, and cell injury, but not ATP depletion in
hippocampal neurons deprived of glucose. Exp Neurol 121:1–13
Min˜ana MD, Hermenegildo C, Llansola M, Montoliu C, Grisolı´a S, and Felipo V
(1996) Carnitina and choline derivates containing a trimethylamine group prevent
ammonia toxicity in mice and glutamate toxicity in primary cultures of neurons.
J Pharmacol Exp Ther 279:194–199.
Min˜ana MD, Montoliu C, Llansola M, Grisolı´a S, and Felipo V (1998) Nicotine
prevents glutamate-induced proteolysis of the microtubule-associated protein
MAP-2 and glutamate neurotoxicity in primary cultures of cerebellar neurons.
Neuropharmacology 37:847–857.
Montoliu C, Llansola M, Kosenko E, Corbala´n R, and Felipo V (1999) Role of cyclic
GMP in glutamate neurotoxicity in primary cultures of cerebellar neurons. Neu-
ropharmacology 38:1883–1891.
Morris RGM, and Davis M (1995) The role of NMDA receptors in learning and
memory, in The NMDA Receptor (Collingridge GL ed) pp 340–376, Oxford Uni-
versity Press, Oxford.
Newton CG (1999) Molecular diversity in drug design. Application to high-speed
synthesis and high-throughput screening, in Molecular Diversity in Drug Design
(Dean PM and Lewis, RA eds) pp 23–42, Kluwer Academic Press, New York.
Olney JW, Ishimaru MJ, Bittigau P, and Ikonomidou C (2000) Ethanol-induced
apoptotic neurodegeneration in the developing brain. Apoptosis 5:515–521.
Ostergaard S and Holm A (1997) Peptomers: a versatile approach for the preparation
of diverse combinatorial peptidomimetic bead libraries. Mol Divers 3:17–27.
Pinilla C, Appel JR, Blanc P, and Houghton RA (1992) Rapid identification of high
affinity peptide ligands using positional scanning synthetic peptide combinatorial
libraries. BioTechniques 13:901–902, 904–905.
Pulsinelli WA and Brierley J (1979) A new model of bilateral hemispheric ischemia
in the unanesthetized rat. Stroke 10:256–272.
Schmidt-Kastner R, Paschen W, Ophoff BG, and Hossmann KA (1989) A modified
four-vessel occlusion model for inducing incomplete forebrain ischemia in rats.
Stroke 20:938–946.
Address correspondence to: Vicente Felipo, Laboratory of Neurobiology,
Instituto de Investigaciones Citolo´gicas, FVIB, Amadeo de Saboya 4, 46010
Valencia, Spain. E-mail: vfelipo@ochoa.fib.es
36 Montoliu et al.
